» Articles » PMID: 15308563

Distinct Types of Primary Cutaneous Large B-cell Lymphoma Identified by Gene Expression Profiling

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2004 Aug 17
PMID 15308563
Citations 56
Authors
Affiliations
Soon will be listed here.
Abstract

In the European Organization for Research and Treatment of Cancer (EORTC) classification 2 types of primary cutaneous large B-cell lymphoma (PCLBCL) are distinguished: primary cutaneous follicle center cell lymphomas (PCFCCL) and PCLBCL of the leg (PCLBCL-leg). Distinction between both groups is considered important because of differences in prognosis (5-year survival > 95% and 52%, respectively) and the first choice of treatment (radiotherapy or systemic chemotherapy, respectively), but is not generally accepted. To establish a molecular basis for this subdivision in the EORTC classification, we investigated the gene expression profiles of 21 PCLBCLs by oligonucleotide microarray analysis. Hierarchical clustering based on a B-cell signature (7450 genes) classified PCLBCL into 2 distinct subgroups consisting of, respectively, 8 PCFCCLs and 13 PCLBCLsleg. PCLBCLs-leg showed increased expression of genes associated with cell proliferation; the proto-oncogenes Pim-1, Pim-2, and c-Myc; and the transcription factors Mum1/IRF4 and Oct-2. In the group of PCFCCL high expression of SPINK2 was observed. Further analysis suggested that PCFCCLs and PCLBCLs-leg have expression profiles similar to that of germinal center B-cell-like and activated B-cell-like diffuse large B-cell lymphoma, respectively. The results of this study suggest that different pathogenetic mechanisms are involved in the development of PCFCCLs and PCLBCLs-leg and provide molecular support for the subdivision used in the EORTC classification.

Citing Articles

Crosstalk of Expression With Patient Mortality, Immunotherapy and Metastasis in Pan-Cancer Based on Integrated Multi-Omics Analyses.

Cao X, Luo N, Liu X, Guo K, Deng M, Lv C Onco Targets Ther. 2025; 18:161-177.

PMID: 39926372 PMC: 11806753. DOI: 10.2147/OTT.S487126.


A Descriptive Study of 103 Primary Cutaneous B-Cell Lymphomas: Clinical and Pathological Characteristics and Treatment from the Spanish Lymphoma Oncology Group (GOTEL).

Martinez-Banaclocha N, Martinez-Madueno F, Caballe B, Badia J, Blanes M, Bujanda D Cancers (Basel). 2024; 16(5).

PMID: 38473391 PMC: 10931196. DOI: 10.3390/cancers16051034.


RARRES1 inhibits hepatocellular carcinoma progression and increases its sensitivity to lenvatinib through interaction with SPINK2.

Guo Y, Chai B, Zhang H, Chai X, Chen Y, Xu J Biol Direct. 2024; 19(1):15.

PMID: 38388961 PMC: 10885466. DOI: 10.1186/s13062-024-00459-0.


IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies.

Parrondo R, Iqbal M, von Roemeling R, von Roemeling C, Tun H Front Immunol. 2023; 14:1239082.

PMID: 37954584 PMC: 10637517. DOI: 10.3389/fimmu.2023.1239082.


[Clinical characteristics and efficacy analysis of 11 patients with primary cutaneous diffuse large B-cell lymphoma, leg type].

Yuan Y, Shi Q, He Y, Qiu H, Yi H, Dong L Zhonghua Xue Ye Xue Za Zhi. 2023; 44(8):690-693.

PMID: 37803847 PMC: 10520235. DOI: 10.3760/cma.j.issn.0253-2727.2023.08.015.